Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10630089 | 0.92 | SLC18A3 (0.43) | SLC18A3SIGMAR1LMNAKDM4EGRIN2B | |
| Hydrochloric Acid SCHEMBL10632236 | 0.91 | SLC18A3 (0.43) | SLC18A3SIGMAR1LMNAKDM4EGRIN2B | |
| SCHEMBL10632309 | 0.91 | SLC18A3 (0.43) | SLC18A3SIGMAR1LMNAGAAKDM4E | |
| SCHEMBL10627836 | 0.89 | SLC6A2 (0.43) | SLC18A3SIGMAR1LMNAOPRM1OPRD1 | |
| SCHEMBL10632529 | 0.89 | CHRNA7 (0.43) | SLC18A3SIGMAR1LMNAGAAKDM4E | |
| SCHEMBL10630176 | 0.88 | SLC6A4 (0.43) | LMNAMEN1KMT2AOPRD1GRIN2B | |
| SCHEMBL10630120 | 0.88 | SLC6A2 (0.43) | SLC18A3SIGMAR1LMNAGAAKDM4E | |
| SCHEMBL10627784 | 0.88 | SLC6A2 (0.41) | SLC18A3MEN1KMT2AKDM4EGRIN2B | |
| SCHEMBL10632281 | 0.88 | SLC6A2 (0.42) | SLC18A3SIGMAR1LMNAMEN1KMT2A | |
| SCHEMBL10627896 | 0.86 | KDM4E (0.39) | SLC18A3SIGMAR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| EP-1732610-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005094896-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-4772705-A | Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines | PENNWALT CORPORATION (US) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | SLC18A3 48/4885SIGMAR1 53/4885LMNA 4352/4885 |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | HTR2A, HTR2C, HTR1A | SLC18A3 48/4885SIGMAR1 53/4885LMNA 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.